No-reflow phenomenon after revascularization in acute ischemic stroke: Achilles' heel of the neurointerventionalist?

您当前的位置：

首页 >

文章列表页 >

No-reflow phenomenon after revascularization in acute ischemic stroke: Achilles' heel of the neurointerventionalist?

Clinical Medicine | 更新时间：2026-01-09

- No-reflow phenomenon after revascularization in acute ischemic stroke: Achilles' heel of the neurointerventionalist?
- Journal of Army Medical University Vol. 44, Issue 1, Pages: 50-59(2022)
- 作者机构：
  
  1.400038 重庆，陆军军医大学（第三军医大学）第一附属医院神经内科
  2.100070 北京，首都医科大学附属天坛医院神经介入中心
- 作者简介：
- 基金信息：
  
  the National Key R & D Program of China(2016YFC1301500)
- DOI：10.16016/j.1000-5404.202112044
  CLC： R741.05;R743.3
- Received：06 December 2021，
  
  Revised：2021-12-13，
  
  Published：15 January 2022
- 稿件说明：
移动端阅览
Kangning CHEN, Zhongrong MIAO. No-reflow phenomenon after revascularization in acute ischemic stroke: Achilles' heel of the neurointerventionalist?[J]. Journal of Army Medical University, 2022, 44(1): 50-59.
DOI：

Kangning CHEN, Zhongrong MIAO. No-reflow phenomenon after revascularization in acute ischemic stroke: Achilles' heel of the neurointerventionalist?[J]. Journal of Army Medical University, 2022, 44(1): 50-59. DOI： 10.16016/j.1000-5404.202112044.

摘要

2015年，多项临床试验证明了血管内再灌注疗法(endovascular reperfusion therapies

EVT) 对大血管闭塞的卒中患者的疗效，改变了世界范围内的卒中治疗指南和临床实践。然而，尽管实现了较高比例脑大血管再通，但是其中约有一半的患者在3个月时显示出较差的神经功能结局。高的脑大血管再通率与低的良好神经功能恢复率之间的差异成为了神经介入医师的痛。艾伯塔卒中研究早期CT评分(Alberta stroke program early CT score，ASPECTS)、直接到达、先前的溶栓、起病到再通时间 < 6 h、再通状况等固然是导致这种差异的原因，但是，我们可能忽视了血管再通不等于组织再灌注这一重要问题。大血管再通后，组织的仍然不良灌注现象被称为无复流现象（no reflow phenomenon

NRP）。冠脉NRP成为了急性冠脉闭塞经皮冠状动脉介入术（percutaneous coronary intervention，PCI）后临床预后的重要预测指标，在过去的近半个世纪，冠脉疾病研究领域就NRP的发病机制、诊断及处理做了大量的探索，切实改善了冠脉PCI的临床疗效。神经科医师在积极进行急性缺血性卒中血管内治疗的同时，是否应该积极关注脑的NRP呢？

Abstract

In 2015

several clinical trials demonstrated the efficacy of endovascular reperfusion therapies (EVT) in stroke patients with large vessel occlusion

which had changed stroke treatment guidelines and clinical practice all over the world. However

despite substantial recanalization

about half of the patients obtain a poor functional outcome at 3 months after endovascular treatment. The difference between the high recanalization rate of cerebral vessels and the low recovery rate of good clinical function has become a pain for neurointerventionalists! Alberta stroke program early CT score (ASPECTS)

direct arrival

previous thrombolysis

time from onset to recanalization < 6 h

and recanalization status

etc. are certainly the reasons for this outcome. But we may have overlooked an important issue

that recanalization of blood vessels does not mean reperfusion of tissues. The phenomenon of poor tissue perfusion after recanalization is called no-reflow phenomenon (NRP). Coronary NRP has become an important predictor of clinical prognosis for acute coronary occlusion after percutaneous coronary intervention (PCI). In the past nearly half century

interventional cardiologists have done a lot of researches on the pathogenesis

diagnosis and treatment of NRP

which effectively improve the clinical efficacy of coronary PCI. When neurointerventionalists are actively carrying out endovascular treatment for acute ischemic stroke

should they actively pay more attention to NRP?

关键词

Keywords

references

CAMPBELL B C V, MITCHELL P J, KLEINIG T J, et al . Endovascular therapy for ischemic stroke with perfusion-imaging selection[J ] . N Engl J Med 2015, 372: 1009-1018. DOI: 10.1056/NEJMoa1414792.

BERKHEMMER O A, FRANSEN P S, BEUMER D, et al . A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med, 2015, 372 (1): 11-20. DOI: 10.1056/NEJMoa1411587.Erratum:NEnglJMed,2015,372(4):394.

JOVIN T G, CHAMORRO A, COBO E, et al . Thrombectomy within 8 hours after symptom onset in ischemic stroke[J ] . N Engl J Med, 2015, 372(24): 2296-2306. DOI: 10.1056/nejmoa150 3780.

GOYAL M, DEMCHUK A M, MENON B K. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med, 2015, 372 (11): 1019-1030. DOI: 10.1056/NEJMoa1414905.

SAVER J L, GOYAL M, BONAFE A, et al . Stent-retriever thrombectomy after intravenous t-PA vs . t-PA alone in stroke[J ] . N Engl J Med, 2015, 372(24): 2285-2295. DOI:10.1056/nejmoa1415061..

WOLLENWEBER F A, TIEDT S, ALEGIANI A, et al . Functional outcome following stroke thrombectomy in clinical practice[J ] . Stroke, 2019, 50(9): 2500-2506. DOI: 10.1161/STROKEAHA.119.026005.

GOYAL M, MENON B K, VAN ZWAM W H, et al . Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials[J ] . Lancet, 2016, 387(10029): 1723-1731. DOI: 10.1016/s0140-6736(16)00163-x.

ALLENCHERRIL J, JNEID H, ATAR D, et al . Pathophysiology, diagnosis, and management of the no-reflow phenomenon[J ] . Cardiovasc Drugs Ther, 2019, 33(5): 589-597. DOI: 10.1007/s10557-019-06901-0.

TOMSICK T. TIMI, TIBI, TICI: I came, I saw, I got confused[J]. Am J Neuroradiol, 2007, 28(2): 382-384.

KLONER R A, GANOTE C E, JENNINGS R B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog[J]. J Clin Invest, 1974, 54(6): 1496-1508. DOI: 10.1172/JCI107898.

DE WAHA S, PATEL M R, GRANGER C B, et al . Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials[J ] . Eur Heart J, 2017, 38(47): 3502-3510. DOI: 10.1093/eurheartj/ehx414.

GUPTA S, GUPTA M M. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction[J]. Indian Heart J, 2016, 68(4): 539-551. DOI: 10.1016/j.ihj.2016.04.006.

OIKONOMOU E, MOUROUZIS K, VOGIATZI G, et al . Coronary microcirculation and the no-reflow phenomenon[J ] . Curr Pharm Des, 2018, 24(25): 2934-2942. DOI: 10.2174/1381612824666180911122230.

SCHWARTZ B G, KLONER R A. Coronary no reflow[J]. J Mol Cell Cardiol, 2012, 52(4): 873-882. DOI: 10.1016/j.yjmcc.2011.06.009.

NISHI T, MURAI T, CICCARELLI G, et al . Prognostic value of coronary microvascular function measured immediately after percutaneous coronary intervention in stable coronary artery disease: an international multicenter study[J ] . Circ Cardiovasc Interv, 2019, 12(9): e007889. DOI: 10.1161/CIRCINTERVENTIONS.119.007889.

TASAR O, KARABAY A K, ODUNCU V, et al . Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J ] . Coron Artery Dis, 2019, 30(4): 270-276. DOI: 10.1097/MCA.0000000000000726.

ROSSINGTON J A, SOL E, MASOURA K, et al . No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case-control study (NORM PPCI)[J ] . Open Heart, 2020, 7(2): e001215. DOI: 10.1136/openhrt-2019-001215.

ALYAMANI M, CAMPBELL S, NAVARESE E, et al . Safety and efficacy of intracoronary thrombolysis as adjunctive therapy to primary PCI in STEMI: a systematic review and meta- analysis[J ] . Can J Cardiol, 2021, 37(2): 339-346. DOI: 10.1016/j.cjca.2020.03.034.

NAGHSHTABRIZI N, SAJEDI M, NAGHSHTABRIZI B, et al . Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon[J ] . Coron Artery Dis, 2020, 31(6): 527-529. DOI: 10.1097/MCA.0000000000000863.

GAO Q J, YANG B, GUO Y, et al . Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis[J ] . Medicine (Baltimore), 2015, 94(32): e1279. DOI: 10.1097/MD.0000000000001279.

KARATHANOS A, LIN Y F, DANNENBERG L, et al . Routine glycoprotein Ⅱb/Ⅲa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis[J ] . Can J Cardiol, 2019, 35(11): 1576-1588. DOI: 10.1016/j.cjca.2019.05.003.

AMES A 3rd, WRIGHT R L, KOWADA M, et al . Cerebral ischemia. Ⅱ. The no-reflow phenomenon[J ] . Am J Pathol, 1968, 52(2): 437-453.

LITTLE J R, KERR F W L, SUNDT Jr T M. Microcirculatory obstruction in focal cerebral ischemia: an electron microscopic investigation in monkeys[J]. Stroke, 1976, 7(1): 25-30. DOI: 10.1161/01.str.7.1.25.

YEMISCI M, GURSOY-OZDEMIR Y, VURAL A, et al . Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery[J ] . Nat Med, 2009, 15(9): 1031-1037. DOI: 10.1038/nm.2022.

EI AMKI M, GLÜCK C, BINDER N, et al . Neutrophils obstructing brain capillaries are a major cause of no-reflow in ischemic stroke[J ] . Cell Rep, 2020, 33(2): 108260. DOI: 10.1016/j.celrep.2020.108260.

KLONER R A, KING K S, HARRINGTON M G. No-reflow phenomenon in the heart and brain[J]. Am J Physiol Heart Circ Physiol, 2018, 315(3): H550-H562. DOI: 10.1152/ajpheart.00183.2018.

BAIRD A E, DONNAN G A, AUSTIN M C, et al . Reperfusion after thrombolytic therapy in ischemic stroke measured by single-photon emission computed tomography[J ] . Stroke, 1994, 25(1): 79-85. DOI: 10.1161/01.str.25.1.79.

KHATRI P, NEFF J, BRODERICK J P, et al . Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IM S-I[J ] . Stroke, 2005, 36(11): 2400-2403. DOI: 10.1161/01.STR.0000185698.45720.58.

DE SILVA D A, FINK J N, CHRISTENSEN S, et al . Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET)[J ] . Stroke, 2009, 40(8): 2872-2874. DOI: 10.1161/STROKEAHA.108.543595.

DALKARA T, ARSAVA E M. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis?[J]. J Cereb Blood Flow Metab, 2012, 32(12): 2091-2099. DOI: 10.1038/jcbfm.2012.139.

RUBIERA M, GARCIA-TOMEL A, OLIVÉ-GADEA M, et al . Computed tomography perfusion after thrombectomy: an immediate surrogate marker of outcome after recanalization in acute stroke[J ] . Stroke, 2020, 51(6): 1736-1742. DOI: 10.1161/STROKEAHA.120.029212.

HIGASHIDA R T, FURLAN A J, ROBERTS H, et al . Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke[J ] . Stroke, 2003, 34(8): e109-e137. DOI: 10.1161/01.STR.0000082721.62796.09.

KHATRI P, HILL M D, PALESCH Y Y, et al . Methodology of the interventional management of stroke (IMS) Ⅲ Trial[J ] . Int J Stroke, 2008, 3(2): 130-137. DOI: 10.1111/j.1747-4949.2008.00151.x.

DF KALLMES. TICI: if you are not confused, then you are not paying attention[J]. Am J Neuroradiol, 2012, 33(5): 975-976. DOI: 10.3174/ajnr.A2905.

FLORES A, RIBÓ M, RUBIERA M, et al . Monitoring of cortical activity postreperfusion. A powerful tool for predicting clinical response immediately after recanalization[J ] . J Neuroimaging, 2015, 25(2): 257-262. DOI: 10.1111/jon.12113.

ZAIDAT O O, LAZZARO M A, LIEBESKIND D S, et al . Revascularization grading in endovascular acute ischemic stroke therapy[J ] . Neurology, 2012, 79(13 Suppl 1): S110-S116. DOI: 10.1212/WNL.0b013e3182695916.

JANG K M, NAM T K, KO M J, et al . Thrombolysis in cerebral infarction grade 2C or 3 represents a better outcome than 2B for endovascular thrombectomy in acute ischemic stroke: a network meta-analysis[J ] . World Neurosurg, 2020, 136: e419-e439. DOI: 10.1016/j.wneu.2020.01.020.

PRASETYA H, RAMOS L A, EPEMA T, et al . qTICI: Quantitative assessment of brain tissue reperfusion on digital subtraction angiograms of acute ischemic stroke patients[J ] . Int J Stroke, 2021, 16(2): 207-216. DOI: 10.1177/1747493020909632.

ADEOYE O, SUCHAREW H, KHOURY J, et al . Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis[J ] . Stroke, 2015, 46(2): 461-464. DOI: 10.1161/STROKEAHA.114.006743.

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Circadian rhythm disorder of blood pressure after stroke and its correlation with stroke prognosis

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Association of 5-factor modified frailty index and controlling nutritional status score with overall survival in patients with unresectable hepatocellular carcinoma undergoing interventional therapy

Related Author

葛建

何明利

刘雨朦

金晶

张栋

高华

WANG Chengfang

ZHOU Yuqin

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰